Clinical evaluation of Kanakasava and Trivrit Churna in the management of Bronchial Asthma (Tamaka Swasa)in the management of Bronchial Asthma (Tamaka Swasa)

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 210 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex with age between 18 to 60 years.
•2.Patients with stable Bronchial Asthma (Tamaka Swasa) (as per GINA Guideline) for at least 6 weeks prior to study entry.
•3.Subjects with intermittent & mild persistent controlled bronchial asthma & show >12 % improvement in FEV1 after bronchodilator.
•4.FEV1 of > 80% of predicted value.
•5.Patients willing to participate and written consent.

•1.Patients with FEV1 < 80% of the predicted value.
•2.Patients with evidence of malignancy.
•3.Patients with uncontrolled Diabetes Mellitus of HbA1c >7.5%.
•4.Patients with unstable cardio vascular disease.
•5.Patients with uncontrolled hypertension
•6.Patients who needs rescue medication daily e.g. Salbutamol inhaler.
•7.Patients suffering from other major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
•8.Patients with concurrent serious hepatic disorder or Renal Disorders
•9.Pulmonary disease other than bronchial asthma.
•10.Smoker/alcoholics and/or drug abusers.
•11.H/o hypersensitivity to the trial drug or any of its ingredients.
•12.Patients who have completed participation in any other clinical trial during the past six (06) months.
•13.Pregnancy or lactating women.

发起方